Adamas Pharma rises after IPO raises $48 million

Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.

The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18.

In morning trading, the stock added $1, or 6.3 percent, to $17.

Adamas Pharmaceuticals Inc. is developing drugs that treat central nervous system disorders such as Parkinson's and Alzheimer's disease. It worked with Forest Laboratories Inc. on Namenda XR, an extended-release version of a Forest drug that treats Alzheimer's. The two companies have been studying a that combines Namenda XR with donepezil, or Aricept. Forest filed for approval of that pill in March.

Shares of the Emeryville, Calif., company are trading under the symbol "ADMS" on the Nasdaq Global Market.

Related Stories

Veeva Systems stock soars on debut

date Oct 16, 2013

Shares of Veeva Systems Inc. are soaring in their trading debut Wednesday after the cloud-based software company raised about $261 million in its initial public offering.

Recommended for you

Teva buying Auspex for $3.2 billion

date 6 hours ago

Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Oral hepatitis B vaccine could become a reality

date 8 hours ago

In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration ...

US aims to cut antibiotic use

date Mar 27, 2015

US President Barack Obama on Friday rolled out plans to cut inappropriate antibiotic use by half, in an effort to tackle drug resistance.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.